(Alliance News) - Stock prices in Europe opened higher early on Friday, with the FTSE 100 almost hitting a new record high, as a swathe of dealmaking was well-received in London. The FTSE 100 index ...

According to reports, the USFDA's Oncologic Advisory Committee voted that the risks from the drug, called Blenrep, outweighed ...

3M reports second-quarter earnings on Friday. Wall Street is looking for earnings per share of $2.01 from sales of $6.1 billion. In the wake of the offer being withdrawn Wednesday, analysts expect a ...

GSK Plc shares tumbled after its blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting ...

Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against ...

GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug ...

"GSK remains confident in the benefit/risk profile of Blenrep and will continue to work closely with the FDA as they complete their review for Blenrep in patients with relapsed or refractory multiple ...

Retail chatter around GSK picked up on Thursday after Blenrep, one of its cancer drugs, hit a roadblock with U.S. regulators.

GSK remains confident in Blenrep’s safety and efficacy, and will work with the FDA as it reviews the drug, the company said ...

The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as the agency’s Oncologic Drugs Advisory ...

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or refractory multiple myeloma who have previously received at least one line of ...